Is Icon Public Limited Company (ICLR) Undervalued?

White Brook Capital Partners, an investment management firm, released its first-quarter 2026 investor letter. A copy of the letter can be downloaded here. The letter indicated that the first quarter of 2026 was a turnaround period. During this quarter, US military actions against Iran and developments in AI dominated economic discussions. These military interventions created a challenging environment for businesses in the following year, due to increased inflation, oil prices, and debt levels. Meanwhile, the outlook for AI remains uncertain and hard to forecast. In addition, please check the Firm’s top five holdings to know its best picks in 2026.

In its first-quarter 2026 investor letter, White Brook Capital Partners highlighted stocks like ICON Public Limited Company (NASDAQ:ICLR). ICON Public Limited Company (NASDAQ:ICLR) is a clinical research organization that provides outsourced development and commercialization services to the pharmaceutical, biotechnology, and medical device industries. On April 22, 2026, ICON Public Limited Company (NASDAQ:ICLR) stock closed at $115.43 per share. One-month return of ICON Public Limited Company (NASDAQ:ICLR) was 11.98%, and its shares lost 20.90% over the past 52 weeks. ICON Public Limited Company (NASDAQ:ICLR) has a market capitalization of about $8.98 billion.

White Brook Capital Partners stated the following regarding ICON Public Limited Company (NASDAQ:ICLR) in its Q1 2026 investor letter:

“ICON Public Limited Company (NASDAQ:ICLR) is a global contract drug manufacturing company we’ve followed for some time but was always too well priced to own. In February, the company disclosed an internal investigation into revenue recognition that would impact revenue by less than 2%. The stock fell 40%. We like the fundamentals of the contract drug manufacturing industry and ICON’s record $24+ billion backlog. Previous to the restatement the company had the opportunity to address its cost structure even while being well positioned in the high-growth oncology and GLP-1/obesity therapeutic segments. We don’t believe the restatement should impact their margin opportunity, their existing contracts, or their ability to win new business and anticipate a significant rally after their formal restatement filing and funds again feel like they can “trust the numbers.” We believe the company trades at a low double digit multiple of free cash flow, a fraction of its historical average and a price that materially underestimates the strength of their business.”

ICON Public Limited Company (NASDAQ:ICLR) is not on our list of 40 Most Popular Stocks Among Hedge Funds Heading Into 2026. According to our database, 41 hedge fund portfolios held ICON Public Limited Company (NASDAQ:ICLR) at the end of the fourth quarter, up from 43 in the previous quarter. While we acknowledge the potential of ICON Public Limited Company (NASDAQ:ICLR) as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.